Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LISATA THERAPEUTICS, INC.CLBS · Entity 7814 | CLO, SVP of Corp Dev | January 13, 2022 | January 18, 2022 |
| Longeveron Inc.LGVN · Entity 7608 | Director | December 21, 2022 | December 22, 2022 |
| PROKIDNEY CORP.PROK · Entity 5181 | Chief Legal Officer | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LISATA THERAPEUTICS, INC.
Report date January 13, 2022 · Filed January 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,985 |
Reported balance
After 2022-01-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-13 · Tax withholding · Disposed 2,563 · Balance 162,985 F1: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 123,000 unvested restricted stock. |
| Common StockSEC Table I · non-derivative | Direct | 160,827 |
Reported balance
After 2022-01-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-01-14 · Tax withholding · Disposed 2,158 · Balance 160,827 F1: Shares withheld as payment of a tax liability on vesting of restricted stock. F3: Includes 119,000 unvested restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld as payment of a tax liability on vesting of restricted stock.
F2: Includes 123,000 unvested restricted stock.
F3: Includes 119,000 unvested restricted stock.
Longeveron Inc.
Report date December 21, 2022 · Filed December 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2032-12-21 | Direct | 5,000 |
Reported balance
After 2022-12-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-21 · Grant · Acquired 5,000 · Balance 5,000 F1: The option vests in four equal annual installments beginning on first anniversary of date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal annual installments beginning on first anniversary of date of grant.
PROKIDNEY CORP.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 327,713 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Conversion · Acquired 163,857 · Balance 327,713 |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-12 · Conversion · Disposed 163,857 · Balance 0 F1: The Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each Class B Common Stock, together with a paired Common Unit, may be exchanged for Class A Common stock on a one-for-one basis. F2: The Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Common Stock do not expire. |
| Common Units in ProKidney Holdings, LLCSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Conversion · Disposed 163,857 · Balance 0 F3: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each Class B Common Stock, together with a paired Common Unit, may be exchanged for Class A Common stock on a one-for-one basis.
F2: The Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Common Stock do not expire.
F3: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:32 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionCommon Units in ProKidney Holdings, LLC · Derivative | 163,857 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-271337 · ownership.xml · derivative · entry 3 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 163,857 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 21:32 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionClass B Common Stock · Derivative | 163,857 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-271337 · ownership.xml · derivative · entry 2 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 163,857 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each Class B Common Stock, together with a paired Common Unit, may be exchanged for Class A Common stock on a one-for-one basis. F2 · derivative.exercise_date: The Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Common Stock do not expire. F2 · derivative.expiration_date: The Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Common Stock do not expire. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 21:32 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionClass A Common Stock | 163,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-271337 · ownership.xml · nonDerivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 12:58 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 600,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001193125-26-086725 · ownership.xml · derivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Class A Common Stock · 600,000 shares Expires 2036-03-01 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:41 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 650,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0000950170-25-032249 · ownership.xml · derivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Class A Ordinary Shares · 650,000 shares Expires 2035-03-01 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2025. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:03 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionCommon Units in ProKidney LP · Derivative | 81,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-089935 · ownership.xml · derivative · entry 3 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,857 Underlying: Class A Ordinary Shares · 81,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:03 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionClass B Ordinary Shares · Derivative | 81,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-089935 · ownership.xml · derivative · entry 2 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,857 Underlying: Class A Ordinary Shares · 81,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire. F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:03 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionClass A Ordinary Shares | 81,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-089935 · ownership.xml · nonDerivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:12 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 234,742 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0000950170-24-025916 · ownership.xml · derivative · entry 2 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,742 Underlying: Class A Ordinary Shares · 234,742 shares Expires 2034-03-01 F2 · derivative.exercise_date: The option vests 50% on the 1st anniversary of March 1, 2024 and the remaining 50% vests in substantially equal monthly installments for 12 months thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:12 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0000950170-24-025916 · ownership.xml · derivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Class A Ordinary Shares · 300,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2024. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 21:07 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionCommon Units in ProKidney LP · Derivative | 81,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011720 · ownership.xml · derivative · entry 3 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,785 Underlying: Class A Ordinary Shares · 81,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 21:07 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionClass B Ordinary Shares · Derivative | 81,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011720 · ownership.xml · derivative · entry 2 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,785 Underlying: Class A Ordinary Shares · 81,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire. F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 21:07 UTC | PROKIDNEY CORP. PROK · Entity 5181 | ConversionClass A Ordinary Shares | 81,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011720 · ownership.xml · nonDerivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2023 Filed Jan 18, 2023 21:11 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 290,000 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001209191-23-003713 · doc4.xml · derivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Class A Ordinary Shares · 290,000 shares Expires 2033-01-16 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 23:00 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantStock Option (Right to buy) · Derivative | 5,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001214659-22-015249 · marketforms-57533.xml · derivative · entry 1 Girolamo Todd C · CIK 0001891257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-12-21 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on first anniversary of date of grant. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:50 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 696,793 | $0.00 Strike: $10.33 | $0.00 |
DisclosureSEC source: 0001209191-22-054429 · doc4.xml · derivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,793 Underlying: Class A Ordinary Shares · 696,793 shares Expires 2032-10-20 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on October 19, 2022. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:29 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantCommon Units in ProKidney LP · Derivative | 327,713 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012370 · dp177005_4-girolamo.xml · derivative · entry 2 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,713 Underlying: Class A Ordinary Shares · 327,713 shares Expires not disclosed F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F4 · derivative.exercise_price: These 327,713 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. F4 · derivative.exercise_date: These 327,713 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. F4 · derivative.expiration_date: These 327,713 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:29 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantClass B Ordinary Shares · Derivative | 327,713 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012370 · dp177005_4-girolamo.xml · derivative · entry 1 Girolamo Todd C · CIK 0001891257 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,713 Underlying: Class A Ordinary Shares · 327,713 shares Expires not disclosed F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. F2 · derivative.exercise_price: These 327,713 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.exercise_date: These 327,713 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.expiration_date: These 327,713 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. Read SEC document |
| February 25, 2022 Filed Feb 25, 2022 23:30 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantCommon stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-003245 · marketforms-55453.xml · nonDerivative · entry 1 Girolamo Todd C · CIK 0001891257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Restricted Stock Units subject to time-based vesting. F2 · balance_after: Includes 5,000 Restricted Stock Units. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 21:04 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 2,158 | $0.82 | $1,770.42 |
DisclosureSEC source: 0001891257-22-000004 · wf-form4_164253988021529.xml · nonDerivative · entry 2 Girolamo Todd C · CIK 0001891257 · CLO, SVP of Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,827 F1 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F3 · balance_after: Includes 119,000 unvested restricted stock. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 21:04 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 2,563 | $0.81 | $2,066.55 |
DisclosureSEC source: 0001891257-22-000004 · wf-form4_164253988021529.xml · nonDerivative · entry 1 Girolamo Todd C · CIK 0001891257 · CLO, SVP of Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,985 F1 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 123,000 unvested restricted stock. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:20 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 4,722 | $0.87 | $4,085.00 |
DisclosureSEC source: 0001891257-22-000002 · wf-form4_164202240462407.xml · nonDerivative · entry 3 Girolamo Todd C · CIK 0001891257 · CLO, SVP of Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,548 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 127,750 unvested restricted stock. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:20 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001891257-22-000002 · wf-form4_164202240462407.xml · derivative · entry 4 Girolamo Todd C · CIK 0001891257 · CLO, SVP of Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-01-10 F5 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:20 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 17,405 | $0.92 | $15,960.39 |
DisclosureSEC source: 0001891257-22-000002 · wf-form4_164202240462407.xml · nonDerivative · entry 2 Girolamo Todd C · CIK 0001891257 · CLO, SVP of Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,270 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 136,500 unvested restricted stock. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:20 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001891257-22-000002 · wf-form4_164202240462407.xml · nonDerivative · entry 1 Girolamo Todd C · CIK 0001891257 · CLO, SVP of Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,675 F1 · shares: Represents 129,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 136,500 unvested restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.